About Molbio Diagnostics IPO
Molbio Diagnostics Ltd. filed its DRHP on August 22, 2025, for an IPO structured as a 100% book-built offer. The total offer size includes a significant fresh issue of up to ₹2,000 crore along with an offer for sale (OFS) of up to 12,556,000 equity shares by existing shareholders.
While the face value of each equity share is ₹1, the specific price band and the closing/opening dates will be announced by the company later. This issue is managed by the specific group of Book Running Lead Managers (BRLMs), including Kotak Mahindra Capital, IIFL Capital Services, Jefferies India and Motilal Oswal Investment Advisors, while KFin Technologies Ltd. serves as the registrar to the issue.
Company Background
Molbio Diagnostics Ltd. was incorporated as "Molbio Diagnostics Private Ltd." in Panaji, Goa, on October 20, 2000. The company developed from a private entity into a public ltd. The company followed a shareholder resolution in November 2024, receiving its fresh certificate of incorporation as Molbio Diagnostics Ltd. on January 16, 2025.
The headquarters of the company is in Verna, Goa, and for over 20 years, the growth of Molbio has been remarkable, from its roots in specialized diagnostics to a globally recognized name in molecular testing. It focuses on making high-end medical technology accessible and affordable at the point of care.
Operations & Product Range
Molbio Diagnostics Ltd. specializes in the development, manufacturing, and sale of molecular diagnostic platforms and kits. The core service involves providing rapid, battery-operated, and "plug-and-play" diagnostic solutions that can operate outside traditional laboratory settings.
Its flagship products include the Truenat real-time PCR platform, which is used for detecting various infectious diseases. Molbio Diagnostics Ltd.’s product range covers a wide spectrum of health challenges, including TB, COVID-19, hepatitis, and other viral and bacterial infections, targeting government health departments, private laboratories, and international health organizations.
Facilities & Capacity
The company maintains dedicated infrastructure for both large-scale production of diagnostic kits and the precision assembly of its molecular diagnostic devices. Molbio Diagnostics Ltd. operates primarily out of its facilities in Goa. These include:
- • Goa Unit I: Located at Verna Industrial Estate, this is a key manufacturing facility for the company.
- • Goa Unit II: Also situated in the Verna Industrial Estate, providing additional manufacturing and operational support.
Brands & Market Presence
The most well-known brand under Molbio Diagnostics Ltd. is Truenat (chip-based molecular diagnostic tests), which has gained international recognition for its role in tuberculosis (TB) screening and diagnosis. The company has a strong domestic presence across India, serving both public and private health sectors.
On the export front, Molbio Diagnostics Ltd. has significant exposure, with revenue from customers outside India reaching ₹197.14 crore for the year ended March 31, 2025. Its technology is widely utilized in global health programs supported by international bodies.
Revenue Streams & Business Model
The main source of revenue for Molbio Diagnostics Ltd. is the sale of its diagnostic products, consisting of hardware (devices) and subsequent sales of consumables (test kits). During the fiscal year 2025, the revenue generated from business activities was ₹1,020.42 crore, where sales of products were ₹997.48 crore, and other operating revenues were ₹22.94 crore in FY 2025. The revenue generated from outside India contributed approximately 19% of the total revenue in FY 2025, registering a significant rise compared to earlier years.
Management & Shareholding
Molbio Diagnostics Ltd. is backed by a set of promoters that has vast experience in the healthcare and trading space. Before the Molbio Diagnostics IPO, the shareholding pattern is dominated by the promoters and major institutional investors such as V Sciences Investments Pte. Ltd. and India Business Excellence Fund III.
Board & Key Management
Molbio Diagnostics Ltd. is led by founders Sriram Natarajan (CEO & Director) and Dr. Chandrasekhar Bhaskaran Nair (Director), who have been central to its technological growth. The board includes Executive Director Sangeetha Sriram, while the management is supported by CFO Amol Narayan Lone and CS Darshan Raghunath Karekar.
Molbio Diagnostics IPO Details
| Detail | Description |
|---|---|
| IPO Date | - |
| Listing Date | - |
| Face Value | ₹ 1 per share |
| Issue Price Band | - |
| Lot Size | - |
| Sale Type | Fresh Capital & OFS |
| Total Issue Size | - |
| Reserved for Market Maker | - |
| Fresh Issue(Ex Market Maker) | [.] shares (agg. up to ₹ 200 Cr) |
| Offer for Sale | 1,25,56,000 shares of ₹1 (agg. up to ₹[.] Cr) |
| Net Offered to Public | - |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Share Holding Pre Issue | 11,27,59,750 shares |
| Share Holding Post Issue | - |
Molbio Diagnostics IPO Financial Information
Latest Revenue
1,027.94
₹ Crore
Profit After Tax
138.58
₹ Crore
Net Worth
952.95
₹ Crore
Total Borrowing
123.16
₹ Crore
| Period Ended | Assets | Revenue From Operations | Profit After Tax | Net Worth | Reserves & Surplus | Total Borrowing | |||
|---|---|---|---|---|---|---|---|---|---|
| 31 Mar 2025 | 1,034.21 | 1,027.94 | 138.58 | 952.95 | 966.13 | 123.16 | |||
| 31 Mar 2024 | 1,221.06 | 840.66 | 83.54 | 807.94 | 821.12 | 174.58 | |||
| 31 Mar 2023 | 1,461.56 | 337.41 | -3.45 | 706.04 | 719.22 | 108.44 | |||
| Amount in ₹ Crore | |||||||||
Molbio Diagnostics Key Performance Indicator
| KPI | Values |
|---|---|
| ROE | 16.20% |
| ROCE | 20.98% |
| Debt/Equity | - |
| RoNW | 15.23% |
| PAT Margin | 13.48% |
| EBITDA Margin | 24.97% |
| Price to Book Value | - |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (Rs) | 12.29 | [.] |
| P/E (x) | [.] | [.] |
IPO Objectives
The proceeds from the Molbio Diagnostics IPO are intended for several strategic purposes. Key IPO objectives are
- • Repayment or prepayment of certain borrowings.
- • Funding capital expenditure for expansion and modernization.
- • Investment in research and development (R&D) to broaden the product portfolio.
- • General corporate purposes.
Conclusion
The Molbio Diagnostics IPO brings a technologically driven healthcare company to the Indian capital markets. The company has built a business model centered on high-volume diagnostic kit sales and a strong hardware platform and has gained an international market reach. By focusing on point-of-care solutions, the company addresses a critical gap in the healthcare infrastructure of developing economies. Through this listing, the company aims to leverage its execution focus and R&D capabilities to tap into further opportunities in the diagnostic industry.
Frequently Asked Questions
Recommended Advisory Services
Ready to take your company public? Explore our specialized IPO advisory services tailored for Indian enterprises.
The India IPO Publication is managed by an editorial team that includes highly experienced finance journalists, market researchers and professionals from the capital markets industry who strive to create high-quality content based on credible sources. Our editors write about IPOs, capital markets, corporate news, capital-raising strategies, regulations and other business matters to ensure our audience stays updated with the latest information. We conduct detailed research and fact-check all information before publishing any content to ensure credibility.
Competitive Strengths
The Truenat platform is a patented, point-of-care molecular diagnostic technology that allows for laboratory-grade testing in field conditions.
Established global footprint and validation from global health organizations.
In-house facilities in Goa allow for end-to-end control over the production of both devices and consumables.
Demonstrated ability to ramp up production and distribution, as seen during the rapid deployment of testing kits in recent years.
| Sr.no | Description | Date | File |
|---|---|---|---|
| 1 | Filed with SEBI/Exchange | 22/08/2025 | View DRHP |
| 2 | SEBI/Exchange approval received | - | - |
Molbio Diagnostics IPO Timeline
| IPO Open Date | - |
| IPO Close Date | - |
| Tentative Allotment | - |
| Initiation of Refunds | - |
| Credit of Shares to Demat | - |
| Tentative Listing Date | - |
| Cut-off time for UPI mandate confirmation | - |
IPO Lot Size
| Investors | No.of lots | Shares Offered | Max Bid Amount |
|---|---|---|---|
| Individual investors (Retail) (Min) | 1 | — | ~₹14,000 - ₹15,000 |
| Individual investors (Retail) (Max) | 13-14 | — | Up to ₹2,00,000 |
| S-HNI (Min) | 14-15 | — | Over ₹2,00,000 |
| S-HNI (Max) | 66-70 | — | Up to ₹10,00,000 |
| B-HNI (Min) | 71+ | — | Over ₹10,00,000 |